Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
---|---|---|---|---|---|---|
Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
Historisch | Analysen |
18.03.2025 07:00:16
|
PolyPeptide publishes invitation to the annual General Meeting 2025
PolyPeptide Group
/ Key word(s): AGMEGM
Media release PolyPeptide publishes invitation to the annual General Meeting 2025 Baar, 18 March 2025 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, published today the invitation to the fourth annual General Meeting, which will take place on 9 April 2025 at the Chollerhalle in Zug. At PolyPeptide Group AG’s (the “Company”) fourth annual General Meeting, which will take place on 9 April 2025 at the Chollerhalle in Zug (the “AGM 2025”), five current members of the Board of Directors will stand for re-election. Beat In-Albon has decided not to stand for re-election as a member of the Board of Directors. The Board of Directors thanks Mr. In-Albon for his dedicated service and valuable contributions. Peter Wilden is proposed for re-election as Chair of the Board of Directors, and Philippe Weber and Peter Wilden as members of the Remuneration and Nomination Committee. As announced on 11 March 2025, the Board of Directors further proposes Jo LeCouilliard for election as new independent member of the Board of Directors, and upon election it is expected that Ms. LeCouilliard will join the Audit and Risk Committee. The Board of Directors further proposes to the AGM 2025 the introduction of a capital band in a new art. 3a of the Company's Articles of Association and the introduction of a conditional share capital for financing purposes and finance instruments in a new art. 3c of the Company's Articles of Association. The capital band shall provide the Board of Directors with the flexibility to increase the Company’s share capital within a predefined range, thereby enhancing the Company's financial and strategic agility. The conditional share capital shall increase the Company's financing and refinancing flexibility. Further proposals include, among others, the re-election of the Statutory Auditors and the Independent Proxy as well as the approval of the maximum aggregate amount of compensation of the Board of Directors and Executive Committee. The shareholders will also be asked to approve the Management Report, Statutory Financial Statements, Consolidated Financial Statements and the report on non-financial matters, in each case, for the financial year 2024 as well as the Remuneration Report 2024 in separate consultative vote. The invitation to the AGM 2025 with the detailed proposals and explanations can be found on the Company’s website. Contact PolyPeptide Group AG Michael Stäheli Head of Investor Relations & Corporate Communications michael.staeheli@polypeptide.com T: +41 43 502 0580 About PolyPeptide PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide- and oligonucleotide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide serves a fast-growing market, offering products and services from pre-clinical through to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with a large exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. For more information, please visit polypeptide.com. @PolyPeptide – follow us on LinkedIn Disclaimer This media release has been prepared by PolyPeptide Group AG and contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual developments to differ materially from those expressed or implied in this release. PolyPeptide Group AG is providing the information in this release as of this date and, except as required by applicable laws or regulations, does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.
End of Media Release |
Language: | English |
Company: | PolyPeptide Group |
Neuhofstrasse 24 | |
6340 Baar | |
Switzerland | |
Phone: | +41435020580 |
E-mail: | mediateam@polypeptide.com |
Internet: | www.polypeptide.com |
ISIN: | CH1110760852 |
Valor: | 111076085 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 2101938 |
End of News | EQS News Service |
|
2101938 18.03.2025 CET/CEST
Nachrichten zu PolyPeptide
28.03.25 |
SPI-Titel PolyPeptide-Aktie: So viel hätten Anleger an einem PolyPeptide-Investment von vor einem Jahr verloren (finanzen.ch) | |
19.03.25 |
Angespannte Stimmung in Zürich: SPI am Mittwochnachmittag im Minus (finanzen.ch) | |
18.03.25 |
PolyPeptide publiziert Einladung zur ordentlichen Generalversammlung 2025 (EQS Group) | |
18.03.25 |
PolyPeptide publishes invitation to the annual General Meeting 2025 (EQS Group) | |
17.03.25 |
Freundlicher Handel: So entwickelt sich der SPI aktuell (finanzen.ch) | |
17.03.25 |
Pluszeichen in Zürich: Zum Start des Montagshandels Gewinne im SPI (finanzen.ch) | |
13.03.25 |
Schwacher Wochentag in Zürich: SPI notiert schlussendlich im Minus (finanzen.ch) | |
13.03.25 |
Starker Wochentag in Zürich: SPI bewegt sich am Mittag im Plus (finanzen.ch) |
Kann man als Privatanleger in die Schweizer Casinobranche investieren? Und wie entwickelt sich das Verhältnis zwischen Online-Casinos und klassischen Spielbanken?
David Kunz (COO der BX Swiss) spricht in diesem Experteninterview mit Björn Zern von Schweizeraktien.net über aktuelle Entwicklungen, Chancen und Herausforderungen in der Welt der Schweizer Casinos.
🎰 In der Schweiz gibt es derzeit 21 konzessionierte Spielbanken, von denen 10 auch eine Online-Gaming-Lizenz besitzen. Doch wie steht es um die wirtschaftliche Lage dieser Unternehmen – und welche sind überhaupt für Anleger zugänglich?
👉🏽 Jetzt auch auf BXplus anmelden und von exklusiven Inhalten rund um Investment & Trading profitieren!
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
US-Börsen mit tiefrotem Wochenausklang -- SMI geht schwächer ins Wochenende -- DAX schliesst im Minus -- Asiens Börsen letztlich tieferDer heimische Aktienmarkt bewegte sich vor dem Wochenende in der Verlustzone, auch der deutsche Aktienmarkt zeigte sich am Freitag von seiner schwachen Seite. Die Wall Street notierte zum Wochenschluss tiefer. Die Börsen in Fernost tendierten zum Wochenende abwärts.
finanzen.net News
Datum | Titel |
---|---|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |